Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering's Antipsychotic Saphris Should Have Easy Advisory Committee Review

This article was originally published in The Pink Sheet Daily

Executive Summary

Label for asenapine could be highly favorable on weight and adverse event issues given FDA's enthusiasm.

You may also be interested in...



Panel Recommends Schering's Saphris; Safety Profile Could Provide Niche

The atypical antipsychotic market should soon be seeing competition from a new entry with a novel formulation and a more attractive safety profile, after an FDA advisory committee voted strongly in favor of Schering Plough's Saphris (asenapine) for acute schizophrenia and bipolar disorder

Panel Recommends Schering's Saphris; Safety Profile Could Provide Niche

The atypical antipsychotic market should soon be seeing competition from a new entry with a novel formulation and a more attractive safety profile, after an FDA advisory committee voted strongly in favor of Schering Plough's Saphris (asenapine) for acute schizophrenia and bipolar disorder

Schering Plough's Saphris Gets Strong Nod From FDA Panel

A safety profile showing less impact on weight and metabolic parameters than other atypical antipsychotics could set asenapine apart in crowded class if it is approved.

Related Content

Topics

UsernamePublicRestriction

Register

PS069760

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel